This is an open-label study to evaluate the safety and tolerability of long-term treatment with pociredir without a comparator in participants with SCD who have previously been treated and shown benefit with pociredir in feeder study 6058-SCD-101 (NCT05169580). Participants in this study will receive once daily doses of pociredir for up to 48 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants reporting Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to Week 196
Number of participants with clinically significant changes in 12-lead Electrocardiogram (ECGs)
Timeframe: Up to Week 196
Number of participants with clinically significant changes in Vital signs
Timeframe: Up to Week 196
Number of participants with clinically significant changes in Clinical laboratory tests
Timeframe: Up to Week 196